Phase 1 data de-risks BMF-650's differentiated GI tolerability profile and one-step titration, supporting partnership discussions. Watch for initiation of longer-term toxicology studies and Phase 2 planning, which are prerequisites for any licensing deal. The company's primary focus on icovamenib diabetes trials means BMF-650 partnership timing is the key catalyst.
Price Chart
Executive Summary
Biomea Fusion reported Phase 1 topline data for BMF-650, its next-generation oral GLP-1 receptor agonist for obesity. In outpatient Cohorts 1-4, mean weight reduction at Day 29 ranged from 1.5% to 3.2% vs 0.1% for placebo, with no severe TEAEs, dose modifications, or discontinuations. A confined Cohort 5 achieved 6.1% weight loss at 400 mg QD with a single one-week titration step and mild GI events (nausea/vomiting 12.5% each). The company plans to advance BMF-650 into longer-term toxicology studies and position it for a strategic partnership, while maintaining primary focus on icovamenib.
Key Facts
- Mean weight reduction at Day 29 across Cohorts 1-4: 1.5% to 3.2% vs 0.1% for pooled placebo
- Cohort 5 (confined, 200 mg→400 mg QD, one-step titration): mean weight reduction 6.1% (6.2 kg) at Day 29
- No severe or serious TEAEs, no TEAE-related dose modifications, no TEAE-related discontinuations across all BMF-650 MAD cohorts (n=40)
- In Cohort 5, nausea and vomiting each reported in 12.5% of participants (1/8), all Grade 1
- BMF-650 achieved target 400 mg QD dose with single one-week titration step; company plans to test a no-titration regimen
- Company intends to position BMF-650 for strategic partnership (licensing) for late-stage development and commercialization
- Primary development focus remains on menin inhibition with icovamenib in type 1 and type 2 diabetes
Financial Impact
No financial figures reported; clinical-stage biotech with no approved products or revenue. Positive Phase 1 data supports potential partnership value for BMF-650 program.
Risk Factors
- Cohort 5 weight loss data confounded by confinement (placebo patients consumed ~33% of provided food); outpatient durability unclear
- Phase 1 data is only 4-week; longer-duration data needed to confirm sustained weight loss and tolerability
- Company prioritizing icovamenib; BMF-650 partnership may take time to materialize
- Highly competitive oral GLP-1 landscape with multiple late-stage candidates
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-420684 |
| Document: d158362dex991.htm | 0001193125-26-420684 |
| Document: d158362dex992.htm | 0001193125-26-420684 |
| Document: 0001193125-26-420684-index-headers.html | 0001193125-26-420684 |
| Document: 0001193125-26-420684-index.html | 0001193125-26-420684 |
| Document: 0001193125-26-420684.txt | 0001193125-26-420684 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6420 (−23.02%) |
Oct 13, 2026 14d ago | Press Release | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6420 (−23.02%) |
Sep 23, 2026 4w ago | Press Release | $1.44 $1.33 | ▼ −7.64% | ▼ −6.96% | $0.6420 (−55.42%) |
Sep 22, 2026 5w ago | 424B5 | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6420 (+55.42%) |
Sep 22, 2026 5w ago | Press Release | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6420 (+55.42%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.17 $1.18 | ▲ +0.85% | ▲ +0.18% | $0.6420 (−45.13%) |
Jun 5, 2026 20w ago | Press Release | $1.15 $1.20 | ▲ +4.35% | ▲ +2.24% | $0.6420 (−44.17%) |
May 11, 2026 24w ago | 8-K | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6420 (−59.37%) |
May 11, 2026 24w ago | Press Release | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6420 (−59.37%) |
Apr 28, 2026 26w ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $0.6420 (−58.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers